Dr. Anthony Tolcher, M.D
Claim this profileNEXT Oncology
Expert in Tumors
Expert in Solid Tumors
36 reported clinical trials
50 drugs studied
About Anthony Tolcher, M.D
Education:
- Earned an MD from the University of British Columbia, Vancouver, Canada.
Experience:
- Completed a Residency in Internal Medicine at the University of Toronto.
- Undertook a Fellowship in Oncology at the University of British Columbia.
- Held a Research Fellowship at the National Cancer Institute, Bethesda, Maryland.
- Served as Director of Clinical Research at START for 10 years and at the Cancer Therapy and Research Center (CTRC) in San Antonio (2003-2007).
- Co-founder and CEO of NEXT Oncology, specializing in the development of new anticancer agents and clinical trials.
Area of expertise
1Tumors
Global LeaderStage IV
Stage III
TP53 negative
2Solid Tumors
Global LeaderStage IV
Stage III
TP53 negative
Affiliated Hospitals
Clinical Trials Anthony Tolcher, M.D is currently running
APG-115 + Pembrolizumab
for Skin Cancer
This study aims to assess the safety, tolerability, pharmacokinetics, and preliminary efficacy of APG-115, an MDM2 inhibitor, either alone or in combination with pembrolizumab, a programmed cell death protein-1 (PD-1) inhibitor, in patients with metastatic melanomas or advanced solid tumors. Our hypothesis is that restoration of the immune response concomitant to inhibition of the MDM2 pathway (which restores p53 functions) may promote cancer cell death, leading to effective anticancer therapy.
Recruiting1 award Phase 1 & 213 criteria
PC14586
for Solid Tumors
This trial is testing a new oral drug, PC14586 (rezatapopt), alone and with pembrolizumab, in patients with advanced cancers that have a specific genetic mutation. The drug aims to fix a mutated protein to help control cancer growth. The study will determine the best dose and evaluate the drug's safety and effectiveness.
Recruiting1 award Phase 1 & 25 criteria
More about Anthony Tolcher, M.D
Clinical Trial Related6 years of experience running clinical trials · Led 36 trials as a Principal Investigator · 8 Active Clinical TrialsTreatments Anthony Tolcher, M.D has experience with
- Pembrolizumab
- ADG106
- ADG116
- HB0025
- HB0036
- BI 907828
Breakdown of trials Anthony Tolcher, M.D has run
Tumors
Solid Tumors
Cancer
Non-Small Cell Lung Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Anthony Tolcher, M.D specialize in?
Anthony Tolcher, M.D focuses on Tumors and Solid Tumors. In particular, much of their work with Tumors has involved Stage IV patients, or patients who are Stage III.
Is Anthony Tolcher, M.D currently recruiting for clinical trials?
Yes, Anthony Tolcher, M.D is currently recruiting for 7 clinical trials in San Antonio Texas. If you're interested in participating, you should apply.
Are there any treatments that Anthony Tolcher, M.D has studied deeply?
Yes, Anthony Tolcher, M.D has studied treatments such as Pembrolizumab, ADG106, ADG116.
What is the best way to schedule an appointment with Anthony Tolcher, M.D?
Apply for one of the trials that Anthony Tolcher, M.D is conducting.
What is the office address of Anthony Tolcher, M.D?
The office of Anthony Tolcher, M.D is located at: NEXT Oncology, San Antonio, Texas 78229 United States. This is the address for their practice at the NEXT Oncology.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.